Open AccessEffective Treatment of a Post-renal Transplantation Patient with Early Recurrent Focal Segmental Glomerulosclerosis and Concomitant Hemolytic Uremic Syndrome, a Case Report
Author(s) -
Abdullah M. Alsawadi,
Majed Aloufi,
Ahmed Fatta,
Sahar Almowaina,
Mugahid Elami,
Hamad Al-Bahili,
Rafat Zahid,
Ali Abdullah Al-Yami
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i53a33671
Subject(s) - eculizumab , medicine , concomitant , plasmapheresis , focal segmental glomerulosclerosis , rituximab , atypical hemolytic uremic syndrome , transplantation , kidney transplantation , renal function , tacrolimus , urology , nephrotic syndrome , thrombotic microangiopathy , gastroenterology , surgery , kidney , glomerulonephritis , immunology , antibody , disease , lymphoma , complement system
While recurrence of primary Focal Segmental Glomerular Sclerosis (FSGS) is common post renal transplantation (30%-80%), a concomitant presentation of hemolytic uremic syndrome (HUS) and recurrent FSGS has never been reported. In addition, treatment of recurrent FSGS and HUS post-renal transplantation is challenging; and usually individualized based on center's experience. Here, we reported a case of a pediatric patient with early recurrence of FSGS and concomitant HUS post-renal transplantation. This patient had a complete hematological and renal response following the administration of Eculizumab and Rituximab, respectively. Withdrawal of Tacrolimus as well as plasmapheresis did not improve kidney function. Therefore, we concluded that both Eculizumab and Rituximab could achieve remission in comparable cases when administered at fixed intervals.